Meyer Handelman CO Relmada Therapeutics, Inc. Transaction History

Meyer Handelman CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 25, 2023	BUY	$2.17 - $35.84 $70,622 - $1.17 Million	32,545 New	32,545 $114,000
Q4 2021 Jan 25, 2022	BUY	$16.93 - $26.82 $70,547 - $111,758	4,167 Added 14.68%	32,545 $733,000
Q1 2021 May 03, 2021	SELL	$31.52 - $39.28 $525,312 - $654,640	-16,666 Reduced 37.0%	28,378 $999,000
Q4 2020 Feb 03, 2021	BUY	$29.88 - $39.8 $497,980 - $663,306	16,666 Added 58.73%	45,044 $1.45 Million
Q1 2020 Apr 22, 2020	SELL	$23.78 - $50.12 $47,560 - $100,240	-2,000 Reduced 6.58%	28,378 $968,000
Q4 2019 Jan 23, 2020	BUY	$10.1 - $47.18 $306,817 - $1.43 Million	30,378 New	30,378 $1.19 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Meyer Handelman CO, based on Form 13F filings with the SEC.

Stay updated on Meyer Handelman CO with notifications on news.